Phillip Lovalenti | Director
Aridis Pharmaceuticals

Phillip M. Lovalenti, Ph.D. is Senior Director R&D at Aridis, with responsibility for product development and CMC. He is also responsible for process development, technical transfer, scale-up and validation activities of both drug substance and drug product manufacturing for all pipeline products. Dr. Lovalenti has more than 20 years of experience in drug development, including formulation and delivery device development for a variety of drug products at ALZA/J&J, Novo Nordisk, and MedImmune/Astra-Zeneca. His product development experience includes Viadur®, FluMist®, Kyprolis®, Synagis® mAb and a number of other monoclonal antibody-based therapeutics. Prior to joining Aridis, he was responsible for the CMC pathway from process development through drug product release for oncology medications in Amgen’s pipeline. He received his Ph.D. in Chemical Engineering at the California Institute of Technology.

Appearances:

Pre-Congress Workshops - November 27 @ 14:00

Workshop A - Antibodies: Discovery vs Computational Design

Series of presentations followed by panel discussion

Computational design of antibodies - Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV - Dr Phillip Lovanti, Sr. Director of R&D, Aridis Pharmaceuticals

Machine learning models for design of antibodies - Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech

Computational and artificial intelligence-based methods for antibody development - Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto

How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School

Moderator: Lisa Purcell, Senior Vice President, Microbiology and Virology, Vir Biotechnology, Inc.